Open Access

Expression of GOLPH3 in patients with non‑small cell lung cancer and xenografts models

  • Authors:
    • Shicong Tang
    • Rirong Yang
    • Xin Zhou
    • Hong Pan
    • Jianlun Liu
  • View Affiliations

  • Published online on: March 23, 2018     https://doi.org/10.3892/ol.2018.8340
  • Pages: 7555-7562
  • Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Increased expression of Golgi phosphoprotein 3 (GOLPH3) has been reported to be associated with several types of human cancer. Patient‑derived cancer xenograft models have demonstrated great potential in preclinical studies. In the present study, the link between GOLPH3 expression and survival was examined in patients with non‑small cell lung cancer (NSCLC). Patient‑derived lung cancer xenograft models were established with two different methods. Lastly, the association between GOLPH3 expression and establishment of the xenograft models was explored. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and immunohistochemistry analysis were used to examine GOLPH3 expression in 60 NSCLC tissues and matched adjacent non‑cancerous tissues (ANT). In addition, tumor pieces from the 60 NSCLC tissues were implanted in the subcutaneous layer and in the subrenal kidney capsule of nude mice. RT‑qPCR, histopathology and immunohistochemistry were used to confirm the human origin of the xenograft tumors. RT‑qPCR was also used to research the mutation status of GOLPH3 in the xenograft tumors. The results demonstrated that NSCLC tissues had higher expression of GOLPH3, at the mRNA and protein level, compared with ANT. High expression of GOLPH3 correlated with poor survival in patients with NSCLC. Successful engraftment was established for 27 tissues in the subrenal kidney capsule and for 16 in the subcutaneous layer of nude mice. The subrenal kidney capsule group demonstrated significantly higher engraftment rates than the subcutaneous layer group. In addition, higher GOLPH3 expression in the tumor tissues was significantly correlated with higher engraftment rates in mice. In both groups, few xenografts lost the GOLPH3 mutation. In summary, GOLPH3 may be an important diagnosis and prognosis indicator in patients with NSCLC. The genotype and phenotype of the xenograft tumors derived from patient lung cancer tissues exhibited significant similarities to the originating primary tumors. High GOLPH3 expression may promote the successful establishment of xenograft models for NSCLC.
View Figures
View References

Related Articles

Journal Cover

May-2018
Volume 15 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tang S, Yang R, Zhou X, Pan H and Liu J: Expression of GOLPH3 in patients with non‑small cell lung cancer and xenografts models. Oncol Lett 15: 7555-7562, 2018.
APA
Tang, S., Yang, R., Zhou, X., Pan, H., & Liu, J. (2018). Expression of GOLPH3 in patients with non‑small cell lung cancer and xenografts models. Oncology Letters, 15, 7555-7562. https://doi.org/10.3892/ol.2018.8340
MLA
Tang, S., Yang, R., Zhou, X., Pan, H., Liu, J."Expression of GOLPH3 in patients with non‑small cell lung cancer and xenografts models". Oncology Letters 15.5 (2018): 7555-7562.
Chicago
Tang, S., Yang, R., Zhou, X., Pan, H., Liu, J."Expression of GOLPH3 in patients with non‑small cell lung cancer and xenografts models". Oncology Letters 15, no. 5 (2018): 7555-7562. https://doi.org/10.3892/ol.2018.8340